Neuracle

Neuracle Medical Technology (Shanghai) Co., Ltd. has registered a cortical electrode, model 1014-35, in the medical device unique identification (UDI) database of China's National Medical Products Administration (NMPA), under registration certificate Guoxiezhuzhun 20263120536. Neuracle's product line spans EEG acquisition equipment and implantable electrodes. The electrode belongs to an implantable EEG electrode kit (cortical electrode, blank electrode, electrode dilator, tunneler, torque wrench, lead fixation clip, fixation screws and electrode protective sleeve) that holds its own registration certificate and is also a component of an implantable BCI hand motor function compensation system. That system comprises a BCI implant, the electrode kit, an EEG signal transceiver, a pneumatic glove, a single-use surgical toolkit, and three software packages for EEG decoding, medical testing and clinical management.

Ten provincial-level regions have issued 12 brain-computer interface (BCI) policy documents as of August 2026, with hard numeric targets almost exclusively set for 2030, which makes the next four years critical for clearing regulatory and payment hurdles. The payment gate is the tightest constraint, as only Zhejiang and Beijing have moved BCI items into basic medical insurance reimbursement, each with conditions attached. This means most provinces still have to solve reimbursement before the 2030 targets can be met.

China's brain-computer interface sector recorded 47 funding rounds in the first half of 2026, 38 of them disclosing terms for a combined RMB 5.38 billion (approx. $750 million). A broader tally used by Chinese financial media puts the total at 64 deals and roughly RMB 7.25 billion (approx. $1 billion). Either figure is more than double the whole of 2025 (49 deals, RMB 2.72 billion) at a comparable deal count. The record lists every deal by month — company, technical approach, round, amount, investors — and identifies three structural patterns: ultrasound and non-invasive approaches moving quickly into a field long defined by implants, Big Tech and municipal state funds entering at the same time, and nearly half of all transactions still sitting at angel or seed stage.

The Shanghai Stock Exchange accepted an IPO application from Neuracle, which is seeking RMB 2.5 billion for BCI product development, industrialization and working capital. The filing shows an established non-invasive neurophysiology equipment business alongside invasive products that still require clinical, regulatory and commercialization spending. Acceptance starts the review process and is not approval to list.

Neuracle Medical Technology (Shanghai) Co., Ltd. ran a clinical trial in China evaluating the safety and efficacy of its implantable wireless brain-computer interface, NEO, in patients with tetraplegia caused by spinal cord injury. The trial is registered on ClinicalTrials.gov as NCT06990412 and is listed as completed; its stated primary purpose was to provide the basis for product registration. NEO is designed to let patients control external devices with brain signals.

Chinese registry ChiCTR2400081380 describes a 96-patient trial of an implantable closed-loop recording and stimulation system for focal drug-resistant epilepsy in people aged 6 to 70. All participants are to receive the implant and then be randomized one month later to active or sham stimulation, 48 per group. The registry provides no evidence that enrollment had passed 50%.